SHH signalling inhibitors effectively dismantle GBM cancer stem cells (CSCs) and prevent tumour recurrence by targeting SHH ligands, SMO, and GLI1 transcription factors at multiple points in the pathway [149]. This evidence concerns the gene GLI1 and glioblastoma.